Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead
Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead
Moderna Inc (NASDAQ:MRNA) stock closed lower by 2.32% on Wednesday, as news around Arbutus Biopharma (NASDAQ:ABUS) impacted investor sentiment. Arbutus has received permission to pursue its patent infringement complaint against Moderna. The claim involves the messenger-RNA technology used in Moderna's Covid vaccine.
由於有關Arbutus Biopharma（納斯達克股票代碼：ABUS）的消息影響了投資者的情緒，Moderna Inc（納斯達克股票代碼：MRNA）股價週三收盤下跌2.32％。Arbutus已獲准對Moderna提起專利侵權投訴。該索賠涉及Moderna的Covid疫苗中使用的Messenger-RNA技術。
Moderna stock has declined by 36.54% over the past year. The past month has seen some recovery in the stock price, which is up 7.6%.
在過去的一年中，摩德納的股票下跌了36.54％。在過去的一個月中，股價有所回升，上漲了7.6％。
While a quick downturn in Moderna stock was expected, perspectives vary among investors. Some view the dip as a chance to buy in at a lower price or average their holdings, while others, more cautious, prefer to stay on the sidelines.
儘管預計Moderna股票將迅速下跌，但投資者的前景各不相同。一些人將下跌視爲以較低的價格買入或平均持倉的機會，而另一些人則更爲謹慎，則傾向於保持觀望。
2024 Calling Out To New Vaccine Launches
2024 年呼籲推出新疫苗
At the business level, Moderna faced challenges in 2023 due to declining demand for its COVID-19 vaccines. However, the company anticipates reasonable revenue in 2024. Despite this, the company maintains a robust pipeline of products, including respiratory vaccines and potential joint flu/COVID-19 vaccines.
在業務層面，由於對其 COVID-19 疫苗的需求下降，Moderna 在 2023 年面臨挑戰。但是，該公司預計2024年的收入將合理。儘管如此，該公司仍擁有強大的產品線，包括呼吸道疫苗和潛在的聯合流感/COVID-19疫苗。
Despite the uncertainty surrounding Moderna's financial outlook, the company maintains a solid cash reserve and continues to invest significantly in R&D to explore new business opportunities. Nonetheless, the company's performance in 2024 could be marked by volatility, compounded by its reliance on the COVID-19 vaccine as its sole product for customers.
儘管圍繞Moderna的財務前景存在不確定性，但該公司仍保持穩健的現金儲備，並繼續在研發方面進行大量投資，以探索新的商機。儘管如此，該公司在 2024 年的業績可能以波動爲標誌，再加上其依賴 COVID-19 疫苗作爲其唯一的客戶產品。
To navigate through 2024-2025 successfully, Moderna may have to introduce its RSV, next-gen COVID, flu, and flu/COVID vaccines.
爲了成功度過2024-2025年，Moderna可能必須推出其呼吸道合胞病毒、下一代冠狀病毒、流感和流感/COVID疫苗。
While the fundamental picture looks hazy, the technicals offer hope.
儘管基本面看起來模糊，但技術面帶來了希望。
Is Moderna Stock Nearing A Golden Cross?
Moderna 股票接近金交叉了嗎？
Chart: Benzinga Pro
圖表：Benzinga Pro
In a significant market development, Moderna's stock apears as though it might be heading towards a Golden Cross, a bullish technical indicator. A Golden Cross signifies the crossing of the stock's 50-day simple moving average (SMA) over its 200-day SMA.
在重大的市場發展中，Moderna的股票似乎可能走向看漲的技術指標金十字。黃金交叉表示該股的50天簡單移動平均線（SMA）突破了200天均線。
Such a development on the charts, if it were to occur, hints at potential upward momentum and positive sentiment among investors.
圖表上的這種事態發展，如果真的發生，則暗示着潛在的上升勢頭和投資者的積極情緒。
A Golden Cross formation would mean growing confidence in Moderna's prospects, particularly as the company continues to innovate in the field of biotechnology, with a focus on developing groundbreaking vaccines and therapeutics. Investors are likely to interpret it as a bullish signal, potentially leading to further appreciation of Moderna's stock value.
金十字會的成立將意味着對Moderna前景的信心不斷增強，尤其是在該公司繼續在生物技術領域進行創新，專注於開發開創性的疫苗和療法之際。投資者可能會將其解釋爲看漲信號，這可能會導致Moderna的股票價值進一步升值。
Now Read: Elon Musk Thinks Tesla Will End Up Making More Batteries For Energy Storage Than EVs: 'Demand For Stationary Batteries Is Super High'
立即閱讀：埃隆·馬斯克認爲特斯拉最終將生產比電動汽車更多的儲能電池：“對固定電池的需求非常高”
Image generated using artificial intelligence via Midjourney.
通過 Midjourney 使用人工智能生成的圖像。
譯文內容由第三人軟體翻譯。